Both HLA-DOA and HLA-DPA1 belong to class II major histocompatibility complex (MHC II) complexes, which have significant association with TME and clinical benefits including patient response to immunotherapy and cancer prognosis, as demonstrated by a pan-cancer association study33. Here, HLA-DPA1 is linked to cancer.